A phase I, multi-center, randomized, double-blind, 2-arm, parallel group trial comparing the pharmacokinetics, safety, immunogenicity and tolerability of the Adalimumab biosimilar, Adessia, and its reference product Humira
Latest Information Update: 13 Mar 2023
At a glance
- Drugs Adalimumab (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
Most Recent Events
- 13 Mar 2023 New trial record
- 24 Feb 2023 According to MiGenTra media release, first participant was dosed in this trial